nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.226	0.5	CiPCiCtD
Vemurafenib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.226	0.5	CiPCiCtD
Vemurafenib—BRAF—hematologic cancer	0.106	0.61	CbGaD
Vemurafenib—ABCG2—hematologic cancer	0.0472	0.271	CbGaD
Vemurafenib—BRAF—Nilotinib—hematologic cancer	0.0369	0.158	CbGbCtD
Vemurafenib—ALB—hematologic cancer	0.0206	0.118	CbGaD
Vemurafenib—ABCC1—Idarubicin—hematologic cancer	0.0127	0.0543	CbGbCtD
Vemurafenib—ABCG2—Clofarabine—hematologic cancer	0.0103	0.0438	CbGbCtD
Vemurafenib—ABCC1—Daunorubicin—hematologic cancer	0.00899	0.0384	CbGbCtD
Vemurafenib—ORM1—Imatinib—hematologic cancer	0.00755	0.0323	CbGbCtD
Vemurafenib—CYP1A2—Anagrelide—hematologic cancer	0.0061	0.0261	CbGbCtD
Vemurafenib—ABCG2—Daunorubicin—hematologic cancer	0.00602	0.0257	CbGbCtD
Vemurafenib—ABCC1—Mitoxantrone—hematologic cancer	0.00546	0.0233	CbGbCtD
Vemurafenib—ABCG2—Teniposide—hematologic cancer	0.00523	0.0223	CbGbCtD
Vemurafenib—ABCG2—Cladribine—hematologic cancer	0.00501	0.0214	CbGbCtD
Vemurafenib—ABCG2—Imatinib—hematologic cancer	0.00461	0.0197	CbGbCtD
Vemurafenib—ABCC1—Epirubicin—hematologic cancer	0.00442	0.0189	CbGbCtD
Vemurafenib—ABCC1—Irinotecan—hematologic cancer	0.0043	0.0184	CbGbCtD
Vemurafenib—ABCG2—Nilotinib—hematologic cancer	0.00419	0.0179	CbGbCtD
Vemurafenib—ABCC1—Vinblastine—hematologic cancer	0.00382	0.0163	CbGbCtD
Vemurafenib—ABCC1—Vincristine—hematologic cancer	0.00376	0.0161	CbGbCtD
Vemurafenib—ABCG2—Dasatinib—hematologic cancer	0.0037	0.0158	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—hematologic cancer	0.00366	0.0156	CbGbCtD
Vemurafenib—ABCC1—Etoposide—hematologic cancer	0.00344	0.0147	CbGbCtD
Vemurafenib—CYP2D6—Lomustine—hematologic cancer	0.00324	0.0138	CbGbCtD
Vemurafenib—CYP1A2—Carmustine—hematologic cancer	0.00321	0.0137	CbGbCtD
Vemurafenib—ALB—Imatinib—hematologic cancer	0.00318	0.0136	CbGbCtD
Vemurafenib—CYP2D6—Idarubicin—hematologic cancer	0.00289	0.0123	CbGbCtD
Vemurafenib—ABCG2—Irinotecan—hematologic cancer	0.00288	0.0123	CbGbCtD
Vemurafenib—CYP1A2—Methoxsalen—hematologic cancer	0.00273	0.0116	CbGbCtD
Vemurafenib—CYP1A2—Bortezomib—hematologic cancer	0.00259	0.0111	CbGbCtD
Vemurafenib—ABCG2—Vincristine—hematologic cancer	0.00252	0.0107	CbGbCtD
Vemurafenib—CYP1A2—Daunorubicin—hematologic cancer	0.00248	0.0106	CbGbCtD
Vemurafenib—CYP2D6—Hydroxyurea—hematologic cancer	0.00246	0.0105	CbGbCtD
Vemurafenib—CYP1A2—Alitretinoin—hematologic cancer	0.00243	0.0104	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—hematologic cancer	0.00235	0.01	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—hematologic cancer	0.00235	0.01	CbGbCtD
Vemurafenib—ABCG2—Etoposide—hematologic cancer	0.00231	0.00985	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—hematologic cancer	0.00228	0.00972	CbGbCtD
Vemurafenib—CYP1A2—Thalidomide—hematologic cancer	0.00226	0.00965	CbGbCtD
Vemurafenib—CYP3A4—Bexarotene—hematologic cancer	0.00222	0.00947	CbGbCtD
Vemurafenib—CYP2D6—Bortezomib—hematologic cancer	0.00214	0.00913	CbGbCtD
Vemurafenib—ALB—Prednisone—hematologic cancer	0.00209	0.00894	CbGbCtD
Vemurafenib—CYP3A4—Busulfan—hematologic cancer	0.00206	0.0088	CbGbCtD
Vemurafenib—CYP3A4—Lomustine—hematologic cancer	0.00206	0.0088	CbGbCtD
Vemurafenib—ALB—Irinotecan—hematologic cancer	0.00198	0.00848	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—hematologic cancer	0.00194	0.0083	CbGbCtD
Vemurafenib—CYP1A2—Imatinib—hematologic cancer	0.0019	0.00812	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—hematologic cancer	0.0019	0.0081	CbGbCtD
Vemurafenib—CYP3A4—Thiotepa—hematologic cancer	0.00184	0.00785	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—hematologic cancer	0.00157	0.00672	CbGbCtD
Vemurafenib—CYP2D6—Imatinib—hematologic cancer	0.00157	0.00669	CbGbCtD
Vemurafenib—CYP1A2—Dasatinib—hematologic cancer	0.00153	0.00652	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—hematologic cancer	0.00152	0.00651	CbGbCtD
Vemurafenib—CYP3A4—Methoxsalen—hematologic cancer	0.00143	0.0061	CbGbCtD
Vemurafenib—CYP2D6—Nilotinib—hematologic cancer	0.00142	0.00608	CbGbCtD
Vemurafenib—CYP2D6—Vinorelbine—hematologic cancer	0.00141	0.00603	CbGbCtD
Vemurafenib—Etoricoxib—MAPK14—hematologic cancer	0.00138	1	CrCbGaD
Vemurafenib—CYP3A4—Bortezomib—hematologic cancer	0.00136	0.0058	CbGbCtD
Vemurafenib—CYP3A4—Daunorubicin—hematologic cancer	0.0013	0.00555	CbGbCtD
Vemurafenib—CYP3A4—Cytarabine—hematologic cancer	0.00115	0.0049	CbGbCtD
Vemurafenib—CYP3A4—Teniposide—hematologic cancer	0.00113	0.00482	CbGbCtD
Vemurafenib—ALB—Methotrexate—hematologic cancer	0.00105	0.00449	CbGbCtD
Vemurafenib—CYP3A4—Ifosfamide—hematologic cancer	0.00104	0.00445	CbGbCtD
Vemurafenib—CYP3A4—Imatinib—hematologic cancer	0.000995	0.00425	CbGbCtD
Vemurafenib—RAF1—Topotecan—Irinotecan—hematologic cancer	0.00099	1	CbGdCrCtD
Vemurafenib—CYP1A2—Etoposide—hematologic cancer	0.00095	0.00406	CbGbCtD
Vemurafenib—CYP3A4—Ruxolitinib—hematologic cancer	0.000937	0.004	CbGbCtD
Vemurafenib—CYP3A4—Nilotinib—hematologic cancer	0.000905	0.00386	CbGbCtD
Vemurafenib—CYP3A4—Vinorelbine—hematologic cancer	0.000897	0.00383	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—hematologic cancer	0.000869	0.00371	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—hematologic cancer	0.00082	0.00351	CbGbCtD
Vemurafenib—CYP3A4—Dasatinib—hematologic cancer	0.000799	0.00342	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—hematologic cancer	0.00079	0.00337	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—hematologic cancer	0.000704	0.00301	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—hematologic cancer	0.000694	0.00297	CbGbCtD
Vemurafenib—RAF1—hematopoietic system—hematologic cancer	0.000692	0.0627	CbGeAlD
Vemurafenib—BRAF—blood—hematologic cancer	0.000689	0.0624	CbGeAlD
Vemurafenib—BRAF—bone marrow—hematologic cancer	0.000666	0.0604	CbGeAlD
Vemurafenib—CYP3A4—Prednisone—hematologic cancer	0.000656	0.0028	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—hematologic cancer	0.000644	0.00275	CbGbCtD
Vemurafenib—CYP3A4—Irinotecan—hematologic cancer	0.000622	0.00266	CbGbCtD
Vemurafenib—BRAF—lung—hematologic cancer	0.000604	0.0547	CbGeAlD
Vemurafenib—BRAF—testis—hematologic cancer	0.00057	0.0516	CbGeAlD
Vemurafenib—CYP3A4—Vinblastine—hematologic cancer	0.000553	0.00236	CbGbCtD
Vemurafenib—CYP3A4—Vincristine—hematologic cancer	0.000543	0.00232	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—hematologic cancer	0.000534	0.00228	CbGbCtD
Vemurafenib—RAF1—gonad—hematologic cancer	0.000527	0.0477	CbGeAlD
Vemurafenib—CYP3A4—Etoposide—hematologic cancer	0.000498	0.00213	CbGbCtD
Vemurafenib—ORM1—hematopoietic system—hematologic cancer	0.000478	0.0433	CbGeAlD
Vemurafenib—RAF1—blood—hematologic cancer	0.000459	0.0416	CbGeAlD
Vemurafenib—RAF1—bone marrow—hematologic cancer	0.000444	0.0402	CbGeAlD
Vemurafenib—BRAF—lymph node—hematologic cancer	0.000413	0.0374	CbGeAlD
Vemurafenib—CYP3A4—Dexamethasone—hematologic cancer	0.000409	0.00175	CbGbCtD
Vemurafenib—RAF1—lung—hematologic cancer	0.000402	0.0364	CbGeAlD
Vemurafenib—RAF1—testis—hematologic cancer	0.000379	0.0344	CbGeAlD
Vemurafenib—CYP3A4—Doxorubicin—hematologic cancer	0.00034	0.00145	CbGbCtD
Vemurafenib—ORM1—blood—hematologic cancer	0.000317	0.0287	CbGeAlD
Vemurafenib—ORM1—bone marrow—hematologic cancer	0.000306	0.0278	CbGeAlD
Vemurafenib—ORM1—lung—hematologic cancer	0.000278	0.0252	CbGeAlD
Vemurafenib—CYP1A2—hematopoietic system—hematologic cancer	0.000276	0.025	CbGeAlD
Vemurafenib—RAF1—lymph node—hematologic cancer	0.000275	0.0249	CbGeAlD
Vemurafenib—ALB—testis—hematologic cancer	0.00023	0.0208	CbGeAlD
Vemurafenib—ABCC1—blood—hematologic cancer	0.000229	0.0208	CbGeAlD
Vemurafenib—ABCC1—lung—hematologic cancer	0.000201	0.0182	CbGeAlD
Vemurafenib—CYP3A4—hematopoietic system—hematologic cancer	0.0002	0.0181	CbGeAlD
Vemurafenib—CYP2D6—hematopoietic system—hematologic cancer	0.000196	0.0178	CbGeAlD
Vemurafenib—ORM1—lymph node—hematologic cancer	0.00019	0.0172	CbGeAlD
Vemurafenib—ABCG2—blood—hematologic cancer	0.00019	0.0172	CbGeAlD
Vemurafenib—ABCC1—testis—hematologic cancer	0.00019	0.0172	CbGeAlD
Vemurafenib—ABCG2—bone marrow—hematologic cancer	0.000184	0.0166	CbGeAlD
Vemurafenib—CYP1A2—blood—hematologic cancer	0.000183	0.0165	CbGeAlD
Vemurafenib—ALB—lymph node—hematologic cancer	0.000167	0.0151	CbGeAlD
Vemurafenib—ABCG2—lung—hematologic cancer	0.000166	0.0151	CbGeAlD
Vemurafenib—CYP1A2—lung—hematologic cancer	0.00016	0.0145	CbGeAlD
Vemurafenib—ABCG2—testis—hematologic cancer	0.000157	0.0142	CbGeAlD
Vemurafenib—ABCC1—lymph node—hematologic cancer	0.000137	0.0125	CbGeAlD
Vemurafenib—CYP3A4—blood—hematologic cancer	0.000132	0.012	CbGeAlD
Vemurafenib—CYP2D6—blood—hematologic cancer	0.00013	0.0118	CbGeAlD
Vemurafenib—ABCG2—lymph node—hematologic cancer	0.000114	0.0103	CbGeAlD
Vemurafenib—CYP2D6—testis—hematologic cancer	0.000108	0.00975	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	1.45e-05	0.000212	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—hematologic cancer	1.45e-05	0.000211	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—hematologic cancer	1.45e-05	0.000211	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—hematologic cancer	1.45e-05	0.000211	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—hematologic cancer	1.45e-05	0.000211	CcSEcCtD
Vemurafenib—Diarrhoea—Irinotecan—hematologic cancer	1.45e-05	0.000211	CcSEcCtD
Vemurafenib—Vomiting—Carmustine—hematologic cancer	1.45e-05	0.00021	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—hematologic cancer	1.44e-05	0.000209	CcSEcCtD
Vemurafenib—Infection—Betamethasone—hematologic cancer	1.44e-05	0.000209	CcSEcCtD
Vemurafenib—Dizziness—Vincristine—hematologic cancer	1.44e-05	0.000209	CcSEcCtD
Vemurafenib—Rash—Carmustine—hematologic cancer	1.43e-05	0.000209	CcSEcCtD
Vemurafenib—Dermatitis—Carmustine—hematologic cancer	1.43e-05	0.000209	CcSEcCtD
Vemurafenib—Vomiting—Alitretinoin—hematologic cancer	1.43e-05	0.000208	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—hematologic cancer	1.43e-05	0.000208	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—hematologic cancer	1.43e-05	0.000208	CcSEcCtD
Vemurafenib—Headache—Carmustine—hematologic cancer	1.42e-05	0.000207	CcSEcCtD
Vemurafenib—Rash—Alitretinoin—hematologic cancer	1.42e-05	0.000207	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—hematologic cancer	1.42e-05	0.000207	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—hematologic cancer	1.42e-05	0.000207	CcSEcCtD
Vemurafenib—Dermatitis—Alitretinoin—hematologic cancer	1.42e-05	0.000207	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	1.42e-05	0.000206	CcSEcCtD
Vemurafenib—Vomiting—Ifosfamide—hematologic cancer	1.42e-05	0.000206	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—hematologic cancer	1.41e-05	0.000206	CcSEcCtD
Vemurafenib—Headache—Alitretinoin—hematologic cancer	1.41e-05	0.000205	CcSEcCtD
Vemurafenib—Diarrhoea—Gemcitabine—hematologic cancer	1.41e-05	0.000205	CcSEcCtD
Vemurafenib—Nausea—Thalidomide—hematologic cancer	1.41e-05	0.000205	CcSEcCtD
Vemurafenib—Rash—Ifosfamide—hematologic cancer	1.4e-05	0.000204	CcSEcCtD
Vemurafenib—Dermatitis—Ifosfamide—hematologic cancer	1.4e-05	0.000204	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—hematologic cancer	1.4e-05	0.000204	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—hematologic cancer	1.4e-05	0.000204	CcSEcCtD
Vemurafenib—Dizziness—Irinotecan—hematologic cancer	1.4e-05	0.000203	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—hematologic cancer	1.39e-05	0.000202	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—hematologic cancer	1.39e-05	0.000202	CcSEcCtD
Vemurafenib—Vomiting—Vincristine—hematologic cancer	1.38e-05	0.000201	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—hematologic cancer	1.38e-05	0.0002	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—hematologic cancer	1.38e-05	0.0002	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—hematologic cancer	1.38e-05	0.0002	CcSEcCtD
Vemurafenib—Rash—Vincristine—hematologic cancer	1.37e-05	0.000199	CcSEcCtD
Vemurafenib—Dermatitis—Vincristine—hematologic cancer	1.37e-05	0.000199	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—hematologic cancer	1.37e-05	0.000199	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—hematologic cancer	1.36e-05	0.000198	CcSEcCtD
Vemurafenib—Headache—Vincristine—hematologic cancer	1.36e-05	0.000198	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—hematologic cancer	1.35e-05	0.000197	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—hematologic cancer	1.35e-05	0.000197	CcSEcCtD
Vemurafenib—Nausea—Carmustine—hematologic cancer	1.35e-05	0.000197	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—hematologic cancer	1.34e-05	0.000196	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—hematologic cancer	1.34e-05	0.000196	CcSEcCtD
Vemurafenib—Vomiting—Irinotecan—hematologic cancer	1.34e-05	0.000196	CcSEcCtD
Vemurafenib—Nausea—Alitretinoin—hematologic cancer	1.34e-05	0.000195	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—hematologic cancer	1.34e-05	0.000194	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—hematologic cancer	1.33e-05	0.000194	CcSEcCtD
Vemurafenib—Rash—Irinotecan—hematologic cancer	1.33e-05	0.000194	CcSEcCtD
Vemurafenib—Dermatitis—Irinotecan—hematologic cancer	1.33e-05	0.000194	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—hematologic cancer	1.33e-05	0.000194	CcSEcCtD
Vemurafenib—Chills—Methotrexate—hematologic cancer	1.33e-05	0.000194	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—hematologic cancer	1.32e-05	0.000193	CcSEcCtD
Vemurafenib—Headache—Irinotecan—hematologic cancer	1.32e-05	0.000193	CcSEcCtD
Vemurafenib—Nausea—Ifosfamide—hematologic cancer	1.32e-05	0.000193	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.32e-05	0.000192	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.32e-05	0.000192	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Vomiting—Gemcitabine—hematologic cancer	1.31e-05	0.000191	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.31e-05	0.00019	CcSEcCtD
Vemurafenib—Rash—Gemcitabine—hematologic cancer	1.3e-05	0.000189	CcSEcCtD
Vemurafenib—Dermatitis—Gemcitabine—hematologic cancer	1.3e-05	0.000189	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—hematologic cancer	1.3e-05	0.000189	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—hematologic cancer	1.3e-05	0.000189	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—hematologic cancer	1.29e-05	0.000188	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—hematologic cancer	1.29e-05	0.000188	CcSEcCtD
Vemurafenib—Headache—Gemcitabine—hematologic cancer	1.29e-05	0.000188	CcSEcCtD
Vemurafenib—Nausea—Vincristine—hematologic cancer	1.29e-05	0.000188	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—hematologic cancer	1.29e-05	0.000187	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—hematologic cancer	1.28e-05	0.000186	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—hematologic cancer	1.26e-05	0.000184	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—hematologic cancer	1.26e-05	0.000184	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—hematologic cancer	1.26e-05	0.000184	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—hematologic cancer	1.26e-05	0.000184	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—hematologic cancer	1.26e-05	0.000184	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Nausea—Irinotecan—hematologic cancer	1.26e-05	0.000183	CcSEcCtD
Vemurafenib—Infection—Prednisone—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—hematologic cancer	1.25e-05	0.000182	CcSEcCtD
Vemurafenib—Chills—Epirubicin—hematologic cancer	1.24e-05	0.000181	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—hematologic cancer	1.24e-05	0.000181	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—hematologic cancer	1.24e-05	0.00018	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—hematologic cancer	1.23e-05	0.000178	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—hematologic cancer	1.22e-05	0.000178	CcSEcCtD
Vemurafenib—Nausea—Gemcitabine—hematologic cancer	1.22e-05	0.000178	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—hematologic cancer	1.22e-05	0.000178	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—hematologic cancer	1.21e-05	0.000177	CcSEcCtD
Vemurafenib—Rash—Cisplatin—hematologic cancer	1.21e-05	0.000176	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—hematologic cancer	1.21e-05	0.000176	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—hematologic cancer	1.21e-05	0.000176	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—hematologic cancer	1.21e-05	0.000176	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—hematologic cancer	1.2e-05	0.000175	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—hematologic cancer	1.2e-05	0.000175	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—hematologic cancer	1.19e-05	0.000173	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—hematologic cancer	1.18e-05	0.000172	CcSEcCtD
Vemurafenib—Hypersensitivity—Triamcinolone—hematologic cancer	1.18e-05	0.000171	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—hematologic cancer	1.17e-05	0.00017	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—hematologic cancer	1.16e-05	0.00017	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—hematologic cancer	1.16e-05	0.000169	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—hematologic cancer	1.16e-05	0.000168	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—hematologic cancer	1.15e-05	0.000168	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.15e-05	0.000167	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—hematologic cancer	1.15e-05	0.000167	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—hematologic cancer	1.14e-05	0.000167	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—hematologic cancer	1.14e-05	0.000167	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—hematologic cancer	1.14e-05	0.000167	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—hematologic cancer	1.14e-05	0.000166	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—hematologic cancer	1.13e-05	0.000165	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—hematologic cancer	1.13e-05	0.000164	CcSEcCtD
Vemurafenib—Cough—Methotrexate—hematologic cancer	1.13e-05	0.000164	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—hematologic cancer	1.12e-05	0.000163	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—hematologic cancer	1.12e-05	0.000163	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—hematologic cancer	1.12e-05	0.000163	CcSEcCtD
Vemurafenib—Rash—Etoposide—hematologic cancer	1.11e-05	0.000161	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—hematologic cancer	1.11e-05	0.000161	CcSEcCtD
Vemurafenib—Headache—Etoposide—hematologic cancer	1.1e-05	0.00016	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—hematologic cancer	1.1e-05	0.00016	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—hematologic cancer	1.1e-05	0.00016	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—hematologic cancer	1.1e-05	0.000159	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—hematologic cancer	1.09e-05	0.000159	CcSEcCtD
Vemurafenib—Rash—Prednisolone—hematologic cancer	1.09e-05	0.000159	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—hematologic cancer	1.09e-05	0.000159	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.09e-05	0.000159	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—hematologic cancer	1.09e-05	0.000158	CcSEcCtD
Vemurafenib—Headache—Prednisolone—hematologic cancer	1.09e-05	0.000158	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—hematologic cancer	1.08e-05	0.000157	CcSEcCtD
Vemurafenib—Constipation—Prednisone—hematologic cancer	1.08e-05	0.000157	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—hematologic cancer	1.05e-05	0.000154	CcSEcCtD
Vemurafenib—Cough—Epirubicin—hematologic cancer	1.05e-05	0.000153	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—hematologic cancer	1.05e-05	0.000153	CcSEcCtD
Vemurafenib—Infection—Methotrexate—hematologic cancer	1.05e-05	0.000152	CcSEcCtD
Vemurafenib—Nausea—Etoposide—hematologic cancer	1.04e-05	0.000152	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—hematologic cancer	1.04e-05	0.000151	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—hematologic cancer	1.04e-05	0.000151	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—hematologic cancer	1.03e-05	0.00015	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—hematologic cancer	1.03e-05	0.00015	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—hematologic cancer	1.03e-05	0.00015	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—hematologic cancer	1.03e-05	0.00015	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—hematologic cancer	1.02e-05	0.000149	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—hematologic cancer	1.02e-05	0.000149	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—hematologic cancer	1.02e-05	0.000149	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.02e-05	0.000149	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—hematologic cancer	1.01e-05	0.000148	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—hematologic cancer	1.01e-05	0.000146	CcSEcCtD
Vemurafenib—Dermatitis—Triamcinolone—hematologic cancer	1e-05	0.000146	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—hematologic cancer	9.99e-06	0.000145	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—hematologic cancer	9.96e-06	0.000145	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—hematologic cancer	9.9e-06	0.000144	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—hematologic cancer	9.9e-06	0.000144	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—hematologic cancer	9.86e-06	0.000143	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—hematologic cancer	9.84e-06	0.000143	CcSEcCtD
Vemurafenib—Infection—Epirubicin—hematologic cancer	9.79e-06	0.000143	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—hematologic cancer	9.75e-06	0.000142	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—hematologic cancer	9.67e-06	0.000141	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	9.6e-06	0.00014	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—hematologic cancer	9.57e-06	0.000139	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—hematologic cancer	9.57e-06	0.000139	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—hematologic cancer	9.57e-06	0.000139	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—hematologic cancer	9.51e-06	0.000138	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—hematologic cancer	9.51e-06	0.000138	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—hematologic cancer	9.47e-06	0.000138	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	9.45e-06	0.000138	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—hematologic cancer	9.28e-06	0.000135	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—hematologic cancer	9.21e-06	0.000134	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—hematologic cancer	9.2e-06	0.000134	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—hematologic cancer	9.2e-06	0.000134	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—hematologic cancer	9.16e-06	0.000133	CcSEcCtD
Vemurafenib—Rash—Betamethasone—hematologic cancer	9.12e-06	0.000133	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—hematologic cancer	9.12e-06	0.000133	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—hematologic cancer	9.12e-06	0.000133	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—hematologic cancer	9.12e-06	0.000133	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—hematologic cancer	9.12e-06	0.000133	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.09e-06	0.000132	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—hematologic cancer	9.08e-06	0.000132	CcSEcCtD
Vemurafenib—Headache—Betamethasone—hematologic cancer	9.07e-06	0.000132	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—hematologic cancer	9.07e-06	0.000132	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—hematologic cancer	9.06e-06	0.000132	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—hematologic cancer	9.04e-06	0.000132	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.98e-06	0.000131	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—hematologic cancer	8.94e-06	0.00013	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—hematologic cancer	8.92e-06	0.00013	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—hematologic cancer	8.86e-06	0.000129	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—hematologic cancer	8.62e-06	0.000126	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—hematologic cancer	8.6e-06	0.000125	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—hematologic cancer	8.6e-06	0.000125	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—hematologic cancer	8.57e-06	0.000125	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—hematologic cancer	8.52e-06	0.000124	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.51e-06	0.000124	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—hematologic cancer	8.5e-06	0.000124	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—hematologic cancer	8.43e-06	0.000123	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—hematologic cancer	8.33e-06	0.000121	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—hematologic cancer	8.33e-06	0.000121	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.31e-06	0.000121	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—hematologic cancer	8.01e-06	0.000117	CcSEcCtD
Vemurafenib—Rash—Prednisone—hematologic cancer	7.95e-06	0.000116	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—hematologic cancer	7.94e-06	0.000116	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—hematologic cancer	7.93e-06	0.000115	CcSEcCtD
Vemurafenib—Headache—Prednisone—hematologic cancer	7.89e-06	0.000115	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	7.87e-06	0.000115	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—hematologic cancer	7.86e-06	0.000114	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—hematologic cancer	7.8e-06	0.000114	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—hematologic cancer	7.79e-06	0.000113	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—hematologic cancer	7.76e-06	0.000113	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—hematologic cancer	7.56e-06	0.00011	CcSEcCtD
Vemurafenib—Nausea—Prednisone—hematologic cancer	7.49e-06	0.000109	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—hematologic cancer	7.45e-06	0.000108	CcSEcCtD
Vemurafenib—Hypersensitivity—Epirubicin—hematologic cancer	7.26e-06	0.000106	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—hematologic cancer	7.21e-06	0.000105	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—hematologic cancer	7.21e-06	0.000105	CcSEcCtD
Vemurafenib—Asthenia—Epirubicin—hematologic cancer	7.07e-06	0.000103	CcSEcCtD
Vemurafenib—Pruritus—Epirubicin—hematologic cancer	6.97e-06	0.000102	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—hematologic cancer	6.96e-06	0.000101	CcSEcCtD
Vemurafenib—Diarrhoea—Epirubicin—hematologic cancer	6.74e-06	9.82e-05	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—hematologic cancer	6.72e-06	9.78e-05	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—hematologic cancer	6.7e-06	9.75e-05	CcSEcCtD
Vemurafenib—Rash—Methotrexate—hematologic cancer	6.64e-06	9.67e-05	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—hematologic cancer	6.63e-06	9.66e-05	CcSEcCtD
Vemurafenib—Headache—Methotrexate—hematologic cancer	6.6e-06	9.6e-05	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—hematologic cancer	6.54e-06	9.53e-05	CcSEcCtD
Vemurafenib—Dizziness—Epirubicin—hematologic cancer	6.52e-06	9.49e-05	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—hematologic cancer	6.45e-06	9.39e-05	CcSEcCtD
Vemurafenib—Vomiting—Epirubicin—hematologic cancer	6.27e-06	9.12e-05	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—hematologic cancer	6.26e-06	9.11e-05	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—hematologic cancer	6.24e-06	9.08e-05	CcSEcCtD
Vemurafenib—Rash—Epirubicin—hematologic cancer	6.21e-06	9.05e-05	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—hematologic cancer	6.21e-06	9.04e-05	CcSEcCtD
Vemurafenib—Headache—Epirubicin—hematologic cancer	6.17e-06	8.99e-05	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—hematologic cancer	6.03e-06	8.78e-05	CcSEcCtD
Vemurafenib—Nausea—Epirubicin—hematologic cancer	5.85e-06	8.52e-05	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—hematologic cancer	5.8e-06	8.44e-05	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—hematologic cancer	5.75e-06	8.37e-05	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—hematologic cancer	5.74e-06	8.36e-05	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—hematologic cancer	5.71e-06	8.32e-05	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—hematologic cancer	5.42e-06	7.89e-05	CcSEcCtD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—hematologic cancer	8.54e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NUP214—hematologic cancer	8.54e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ACP5—hematologic cancer	8.52e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CA9—hematologic cancer	8.52e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—hematologic cancer	8.51e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1B—hematologic cancer	8.51e-07	1.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—hematologic cancer	8.5e-07	1.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—hematologic cancer	8.47e-07	1.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.45e-07	1.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOR2—hematologic cancer	8.4e-07	1.43e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—EP300—hematologic cancer	8.38e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK8—hematologic cancer	8.37e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—hematologic cancer	8.37e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTR—hematologic cancer	8.36e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCG2—hematologic cancer	8.36e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—hematologic cancer	8.36e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—hematologic cancer	8.36e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—hematologic cancer	8.36e-07	1.42e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—hematologic cancer	8.28e-07	1.41e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—hematologic cancer	8.27e-07	1.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3R1—hematologic cancer	8.22e-07	1.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTPN11—hematologic cancer	8.21e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—hematologic cancer	8.2e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—hematologic cancer	8.16e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—hematologic cancer	8.15e-07	1.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—hematologic cancer	8.13e-07	1.38e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CREBBP—hematologic cancer	8.08e-07	1.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—hematologic cancer	8.06e-07	1.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—hematologic cancer	8.01e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH1—hematologic cancer	8.01e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK3—hematologic cancer	8e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—hematologic cancer	8e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	8e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—hematologic cancer	7.95e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREB1—hematologic cancer	7.95e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—hematologic cancer	7.94e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—hematologic cancer	7.93e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—hematologic cancer	7.92e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTO1—hematologic cancer	7.92e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TXN—hematologic cancer	7.92e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCC3—hematologic cancer	7.92e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—hematologic cancer	7.9e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—hematologic cancer	7.88e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—hematologic cancer	7.85e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—hematologic cancer	7.85e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—hematologic cancer	7.84e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.83e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—hematologic cancer	7.83e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK8—hematologic cancer	7.82e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD44—hematologic cancer	7.8e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NQO1—hematologic cancer	7.8e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—hematologic cancer	7.78e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SDC1—hematologic cancer	7.77e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6R—hematologic cancer	7.76e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SPHK1—hematologic cancer	7.75e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREBBP—hematologic cancer	7.75e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—hematologic cancer	7.66e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—hematologic cancer	7.65e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—hematologic cancer	7.63e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—hematologic cancer	7.63e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.63e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—hematologic cancer	7.59e-07	1.29e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—hematologic cancer	7.56e-07	1.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—hematologic cancer	7.53e-07	1.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—hematologic cancer	7.5e-07	1.27e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—hematologic cancer	7.47e-07	1.27e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—hematologic cancer	7.46e-07	1.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—hematologic cancer	7.45e-07	1.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	7.44e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.43e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—hematologic cancer	7.42e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAP2K1—hematologic cancer	7.39e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYCS—hematologic cancer	7.38e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—hematologic cancer	7.35e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	7.34e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.33e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—hematologic cancer	7.33e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—hematologic cancer	7.31e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—hematologic cancer	7.28e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—hematologic cancer	7.26e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NCOR1—hematologic cancer	7.24e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—hematologic cancer	7.24e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	7.24e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CRABP1—hematologic cancer	7.24e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3R1—hematologic cancer	7.24e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—hematologic cancer	7.22e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—hematologic cancer	7.19e-07	1.22e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—hematologic cancer	7.15e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—hematologic cancer	7.13e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—hematologic cancer	7.13e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—hematologic cancer	7.07e-07	1.2e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALOX5—hematologic cancer	7.06e-07	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—hematologic cancer	7.05e-07	1.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—hematologic cancer	7.03e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.01e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—hematologic cancer	7e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—hematologic cancer	6.99e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3R1—hematologic cancer	6.94e-07	1.18e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NUP98—hematologic cancer	6.83e-07	1.16e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—hematologic cancer	6.83e-07	1.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—hematologic cancer	6.75e-07	1.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—hematologic cancer	6.74e-07	1.15e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JAK2—hematologic cancer	6.74e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—hematologic cancer	6.69e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—hematologic cancer	6.68e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—hematologic cancer	6.65e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADCY7—hematologic cancer	6.63e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA3—hematologic cancer	6.63e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—hematologic cancer	6.63e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—hematologic cancer	6.61e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD44—hematologic cancer	6.61e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—hematologic cancer	6.61e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NUP214—hematologic cancer	6.59e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—hematologic cancer	6.58e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—hematologic cancer	6.58e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—hematologic cancer	6.57e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—hematologic cancer	6.57e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—hematologic cancer	6.56e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—hematologic cancer	6.55e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—hematologic cancer	6.51e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—hematologic cancer	6.51e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—hematologic cancer	6.49e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.47e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTR—hematologic cancer	6.45e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG2—hematologic cancer	6.45e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MTOR—hematologic cancer	6.4e-07	1.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—hematologic cancer	6.4e-07	1.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTHFR—hematologic cancer	6.4e-07	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—hematologic cancer	6.33e-07	1.07e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—hematologic cancer	6.25e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYCS—hematologic cancer	6.25e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	6.21e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—hematologic cancer	6.2e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—hematologic cancer	6.16e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—hematologic cancer	6.14e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—hematologic cancer	6.14e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—hematologic cancer	6.11e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—hematologic cancer	6.07e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—hematologic cancer	6.04e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—hematologic cancer	6.01e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—hematologic cancer	6.01e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SDC1—hematologic cancer	6e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—hematologic cancer	5.99e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NCOR1—hematologic cancer	5.98e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—hematologic cancer	5.98e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—hematologic cancer	5.89e-07	1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—hematologic cancer	5.88e-07	9.99e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—hematologic cancer	5.85e-07	9.94e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—hematologic cancer	5.77e-07	9.8e-06	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—hematologic cancer	5.73e-07	9.74e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—hematologic cancer	5.73e-07	9.74e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—hematologic cancer	5.72e-07	9.71e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—hematologic cancer	5.64e-07	9.58e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.64e-07	9.58e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.59e-07	9.5e-06	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—hematologic cancer	5.59e-07	9.49e-06	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—hematologic cancer	5.57e-07	9.47e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—hematologic cancer	5.55e-07	9.42e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—hematologic cancer	5.53e-07	9.4e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—hematologic cancer	5.52e-07	9.38e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—hematologic cancer	5.51e-07	9.36e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—hematologic cancer	5.5e-07	9.35e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—hematologic cancer	5.46e-07	9.27e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK8—hematologic cancer	5.41e-07	9.19e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—hematologic cancer	5.4e-07	9.17e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—hematologic cancer	5.38e-07	9.13e-06	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—hematologic cancer	5.35e-07	9.08e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.33e-07	9.06e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTHFR—hematologic cancer	5.29e-07	8.98e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—hematologic cancer	5.28e-07	8.96e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—hematologic cancer	5.22e-07	8.86e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—hematologic cancer	5.22e-07	8.86e-06	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—hematologic cancer	5.16e-07	8.76e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—hematologic cancer	5.13e-07	8.71e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—hematologic cancer	5.11e-07	8.68e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD44—hematologic cancer	5.1e-07	8.66e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—hematologic cancer	5.1e-07	8.66e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—hematologic cancer	5.07e-07	8.6e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NCOR1—hematologic cancer	5.07e-07	8.6e-06	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—hematologic cancer	5.06e-07	8.6e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—hematologic cancer	5e-07	8.49e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—hematologic cancer	5e-07	8.48e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CREBBP—hematologic cancer	4.99e-07	8.47e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—hematologic cancer	4.95e-07	8.4e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—hematologic cancer	4.94e-07	8.38e-06	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—hematologic cancer	4.94e-07	8.38e-06	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—hematologic cancer	4.93e-07	8.38e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—hematologic cancer	4.89e-07	8.31e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYCS—hematologic cancer	4.83e-07	8.2e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	4.8e-07	8.15e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—hematologic cancer	4.73e-07	8.03e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—hematologic cancer	4.73e-07	8.03e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—hematologic cancer	4.63e-07	7.86e-06	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—hematologic cancer	4.61e-07	7.83e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—hematologic cancer	4.6e-07	7.81e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—hematologic cancer	4.59e-07	7.79e-06	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—hematologic cancer	4.55e-07	7.73e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—hematologic cancer	4.51e-07	7.67e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTHFR—hematologic cancer	4.48e-07	7.6e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3R1—hematologic cancer	4.46e-07	7.58e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—hematologic cancer	4.44e-07	7.54e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.25e-07	7.23e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—hematologic cancer	4.25e-07	7.22e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—hematologic cancer	4.12e-07	7e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CREBBP—hematologic cancer	4.12e-07	6.99e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—hematologic cancer	4.07e-07	6.91e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.03e-07	6.84e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.95e-07	6.7e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.91e-07	6.64e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.91e-07	6.64e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.9e-07	6.63e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—hematologic cancer	3.9e-07	6.63e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—hematologic cancer	3.85e-07	6.55e-06	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—hematologic cancer	3.78e-07	6.42e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—hematologic cancer	3.78e-07	6.41e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—hematologic cancer	3.76e-07	6.39e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.69e-07	6.26e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—hematologic cancer	3.61e-07	6.13e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—hematologic cancer	3.56e-07	6.05e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CREBBP—hematologic cancer	3.49e-07	5.92e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—hematologic cancer	3.46e-07	5.87e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTHFR—hematologic cancer	3.46e-07	5.87e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—hematologic cancer	3.4e-07	5.78e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—hematologic cancer	3.4e-07	5.77e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—hematologic cancer	3.33e-07	5.65e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—hematologic cancer	3.31e-07	5.62e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—hematologic cancer	3.26e-07	5.54e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—hematologic cancer	3.19e-07	5.42e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.12e-07	5.3e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—hematologic cancer	2.94e-07	4.99e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.9e-07	4.93e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.88e-07	4.9e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—hematologic cancer	2.8e-07	4.76e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.69e-07	4.57e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.55e-07	4.33e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—hematologic cancer	2.52e-07	4.28e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—hematologic cancer	2.51e-07	4.27e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—hematologic cancer	2.49e-07	4.23e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.41e-07	4.09e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—hematologic cancer	2.38e-07	4.03e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.22e-07	3.78e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—hematologic cancer	2.07e-07	3.52e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—hematologic cancer	2.05e-07	3.49e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—hematologic cancer	1.92e-07	3.26e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—hematologic cancer	1.83e-07	3.11e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.76e-07	2.98e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—hematologic cancer	1.69e-07	2.88e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—hematologic cancer	1.44e-07	2.44e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.36e-07	2.3e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—hematologic cancer	1.11e-07	1.88e-06	CbGpPWpGaD
